Skip to search formSkip to main contentSkip to account menu

CI 979

Known as: CI-979, CI979 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

dihydropyridinemilameline

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2002
2002
Interaction of a Muscarinic Cholinergic Agonist on Acetylcholine and Dopamine Receptors in the Monkey Brain Studied with Positron Emission Tomography
The effects on the binding to cholinergic and dopaminergic receptors in the brain during continuous intravenous infusion of the… 
1997
1997
Regional brain distribution and binding of the muscarinic receptor agonist CI-979 studied by positron emission tomography in the monkey.
The regional brain distribution and selective binding of the cholinergic muscarinic receptor agonist CI-979 labelled with 11C was… 
1996
1996
Toxicological comparison of a muscarinic agonist given to rats by gavage or in the diet.
Review
1995
Review
1995
Cholinergic therapies for Alzheimer's disease. Palliative or disease altering?
Loss of cholinergic function in the neocortex and hippocampus arising from death or atrophy of basal forebrain cholinergic… 
1995
1995
The Target Population in Phase I Clinical Trials of Cholinergic Compounds in Alzheimer Disease: The Role of the “Bridging Study”
Our experience with studies investigating central nervous system active compounds in Alzheimer disease (AD) patients suggest that… 
1993
1993
Measurement of CI-979 (a candidate drug for the treatment of age-related disorders of cognition) in human plasma by capillary gas chromatography with nitrogen-selective detection.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)